FNS  Vol.4 No.10 , October 2013
Inflammatory Biomarkers in Asian Indian Women with Metabolic Syndrome
Abstract: Cardiovascular diseases (CVD) are the leading cause of mortality necessitating its early detection. The emergence of newer subclinical biomarkers in addition to the known cardiometabolic risk factors may play an important role in early detection of CVD risk. In the present study, 74 adult females (30 - 75 y) with metabolic syndrome (MS) were selected and additional biochemical parameters such as C-reactive protein (CRP) and Homocysteine (Hcy) levels were analyzed. The average body mass index (BMI) and waist circumference of subjects were found to be 30 kg/m2 and99 cmrespectively. Mean LDL levels were found to be much higher than normal (139 mg/dl) while the HDL levels were low (41.5 mg/dl). The average fasting blood sugar and insulin levels were within the normal range. However, 40.5% females had serum Hcy levels >13.2 μmol/l and 59.5% women had CRP levels >3 mg/L indicating increased risk of CVD. Higher Hcy levels were associated with hyperinsulinemia (p < 0.01) and hyperglycemia (p < 0.05), indicating predilection for glucose intolerance. CRP levels showed significant negative correlation with HDL (p < 0.05), indicating a predilection for glucose intolerance. The present study reports overall more than 40% MS women are classified as high risk group using the Western standards. Limited data on normal levels of inflammatory biomarkers are available for Asian Indians. The study results indicate the importance of Hcy and CRP values among females having metabolic syndrome, known to be at a high risk of CVD.
Cite this paper: P. Singhania, G. Gupta and K. Ray, "Inflammatory Biomarkers in Asian Indian Women with Metabolic Syndrome," Food and Nutrition Sciences, Vol. 4 No. 10, 2013, pp. 1021-1027. doi: 10.4236/fns.2013.410133.

[1]   K. G. M. M. Alberti, P. Zimmet and J. Shaw, “Metabolic Syndrome—A New World-Wide Definition. A Consensus Statement from the International Diabetes Federation,” Diabetic Medicine, Vol. 23, No. 5, 2006, pp. 469480.

[2]   M. Thiruvagounder, S. Kha and D. S. Sheriff, “The Prevalence of Metabolic Syndrome in a Local Population in India,” Biochemia Medica, Vol. 20, No. 2, 2010, pp. 249252.

[3]   S. Kanjilal, J. Shanker, V. S. Rao, N. B. Khadrinarasimhaih, M. Mukherjee, S. S. Iyengar and V. V. Kakkar, “Prevalence and Component Analysis of Metabolic Syndrome: An Indian Atherosclerosis Research Study Perspective,” Vascular Health Risk Management, Vol. 4, No. 1, 2008, pp. 189-197.

[4]   A. Ramachandran, I. Sathyamuthy, C. Snehaltha, K. Satyavani, S. Sivasankari, J. Misra, M. R. Girinath and V. Viswanathan, “Risk Variable for Coronary Artery Disease in Asian Indians,” American Journal of Cardiology, Vol. 88, No. 2, 2001, pp. 201-202.

[5]   A. Misra, J. W. Singh and R. M. Pandey, “An Evaluation of Candidate Definitions of the Metabolic Syndrome in Adult Asian Indians,” Diabetes Care, Vol. 28, No. 2, 2005, pp. 398-403.

[6]   C. Tan, S. K. Chew, M. Stefan, et al., “Can We Apply the NCEP-ATP Definition of the Metabolic Syndrome to Asians?” Diabetes Care, Vol. 27, No. 5, 2004, pp. 11821186.

[7]   T. Shah, S. S. Jonnalagadda, J. R. Kicklighter, et al., “Prevalence of Metabolic Syndrome Risk Factors among Young Adult Asian Indians,” Journal of Immigrant Health, Vol. 7, No. 2, 2005, pp. 117-126.

[8]   M. Wei, B. D. Mitchell, S. M. Haffner and M. P. Stern, “Effects of Cigarette Smoking, Diabetes, High Cholesterol, and Hypertension on All Cause Mortality and Cardiovascular Disease Mortality in Mexican Americans. The San Antonio Heart Study,” American Journal of Epidemiology, Vol. 144, No. 11, 1996, pp. 1058-1065.

[9]   D. S. Buchan, N. E. Thomas and J. S. Baker, “Novel Risk Factors of Cardiovascular Disease and Their Associations between Obesity, Physical Activity and Physical Fitness,” Journal of Public Health Research, Vol. 1, No. 11, 2012, pp. 59-66.

[10]   G. F. Gensini, M. Comeglio and A. Colella, “Classical Risk Factor and Emerging Elements in the Risk Profile for Coronary Artery Disease,” European Heart Journal, Vol. 195, 1998, pp. 53A-61A.

[11]   R. B. Harish, V. Govindaraju and C. N. Manjunath, “Risk Prediction-Homocysteine in Coronary Heart Disease,” Indian Journal of Clinical Biochemistry, Vol. 22, No. 1, 2007, pp. 18-21.

[12]   K. S. McCully, “Vascular Pathology of Homocysteinemia: Implications for the Pathogenesis of Arteriosclerosis,” American Journal of Pathology, Vol. 56, No. 1, 1959, pp. 111-128.

[13]   R. Carmel, P. V. Mallidi, S. Vinarskiy, S. Brar and Z. Frouhar, “Hyperhomocysteinemia and Cobalamin Deficiency in Young Asian Indians in the United States,” American Journal of Hematology, Vol. 70, No. 2, 2002, pp. 107114.

[14]   P. E. Szmitko, C. H. Wang, R. D. Weisel, J. R. de Almeida, T. J. Anderson and S. Verma, “New Markers of Inflammation and Endothelial Cell Activation: Part I,” Circulation, Vol. 108, 2003, pp. 1917-1923.

[15]   M. Pepys, “C-Reactive Protein Fifty Years On,” Lancet, Vol. 317, No. 8221, 1981, pp. 653-657.

[16]   L. M. Biasucci, “C-Reactive Protein and Secondary Prevention of Coronary Events,” Clinica Chimica Acta, Vol. 311, 2001, pp. 49-52.

[17]   F. Haverkate, S. G. Thompson, S. D. Pyke, et al., “Production of C-Reactive Protein and Risk of Coronary Events in Stable and Unstable Angina: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group,” Lancet, Vol. 349, No. 9050, 1997, pp. 462-466.

[18]   D. Heng, S. Ma, J. J. M. Lee, B. C. Tai, K. H. Mak, K. Hughes, et al., “Modification of the NCEP ATP III Definitions of the Metabolic Syndrome for Use in Asians Identifies Individuals at Risk of Ischemic Heart Disease,” Atherosclerosis, Vol. 186, No. 2, 2006, pp. 367-373.

[19]   P. Trinder, “Determination of Glucose in Blood Using Glucose Oxidase with an Alternative Oxygen Acceptor,” Annals of Clinical Biochemistry, Vol. 6, No. 2, 1969, pp. 24-27.

[20]   G. Schettler and E. Nüssel, Arbeitsmed Sozialmed Praventivmed, Vol. 10, No. 25, 1975.

[21]   W. Richmond, “Preparation and Properties of a Cholesterol Oxidase from Nocardia sp. and Its Application to the Enzymatic Assay of Total Cholesterol in Serum,” Clinical Chemistry, Vol. 19, No. 12, 1973, pp. 1350-1356.

[22]   P. Roeschlau, “Enzymatische Bestimmung das GesamtChoiesterins in Serum,” Zeitschrift für Klinische Chemie und Klinische Biochemie, Vol. 12, 1974, pp. 403-407.

[23]   P. D. Mayne, “Fat Metabolism,” In: Clinical Chemistry in Diagnosis and Treatment, Vol. 11. 6th Edition, Oxford University Press Inc., New York, 1994, p. 224.

[24]   N. J. Jacobe and P. J. Van Demark, “The Purification and Properties of the α-Glycerophosphate-Oxidizing Enzyme of Streptococcus faecalis 10C1,” Archives of Biochemistry and Biophysics, Vol. 88, No. 2, 1960, pp. 250-255.

[25]   P. Trinder, “Triglycerides Estimation by GPO-PAP Method,” Annals of Clinical Biochemistry, Vol. 6, No. 24, 1969, pp. 24-27.

[26]   M. Werner, D. G. Gabrielson and J. Eastman, “Ultramicro Determination of Serum Triglycerides by Bioluminescent Assay,” Clinical Chemistry, Vol. 27, No. 2, 1981, pp. 268271.

[27]   L. K. Koditschek and W. W. Umbreit, “Alpha-Glycerophosphate Oxidase in Streptococcus faecium F 24,” Journal of Bacteriology, Vol. 98, No. 3, 1969, pp. 10631068.

[28]   W. P. Castelli, J. T. Doyle, T. Gordon, C. G. Hames, M. C. Hjortland, S. B. Hulley, A. Kagan and W. J. Zukel, “HDL Cholesterol and Other Lipids in Coronary Heart Disease: Cooperative Lipoprotein Phenotyping Study,” Circulation, Vol. 55, No. 5, 1977, pp. 767-772.

[29]   M. Burstein, H. R. Scholnic and R. Morfin, “Rapid Method for the Isolation of Lipoproteins from Human Serum by Precipitation with Polyanion,” The Journal of Lipid Research, Vol. 11, No. 6, 1970, pp. 583-595.

[30]   D. S. Young, “Effects of Drugs on Clinical Laboratory Tests,” 3rd Edition, AACC Press, Washington, DC, Vol. 3, 1990, pp. 104-106.

[31]   N. W. Tietz, “Textbook of Clinical Chemistry,” W.B. Saunders, Philadelphia, 1986, pp. 874-881.

[32]   W. Hohenwallner, R. Sommer, E. Wimmer and G. V. Tschurtschenthaler, Clinical Chemistry, Vol. 26, 1980, pp. 177, 178.

[33]   N. W. Tietz, P. R. Finley and E. L. Pruden, “Clinical Guide to Laboratory Tests,” 2nd Edition, W.B. Saunders, Philadelphia, 1990, pp. 304-306.

[34]   W. T. Friedewald, R. I. Levy and D. S. Fredrickson, “Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, without Use of the Preparative Ultracentrifuge,” Clinical Chemistry, Vol. 18, No. 6, 1972, pp. 499-502.

[35]   H. Lars-Olof, et al., Current Opinion in Infect Diseases, Vol. 10, 1997, pp. 196-201.

[36]   C. Vaishnavi, Immunology and Infectious Diseases, Vol. 6, 1996, pp. 139-144.

[37]   Y. Hokama, et al., Journal of Clinical Laboratory Status, Vol. 1, 1987, pp. 15-27.

[38]   K. Pulki, et al., Scandinavian Journal of Clinical & Laboratory Investigation, Vol. 46, 1986, pp. 606-607.

[39]   W. Müller, et al., “Interference of IgM Rheumatoid Factor with Nephelometric C-Reactive Protein Determinations,” Journal of Immunological Methods, Vol. 80, No. 1, 1985, pp. 77-90.

[40]   S. Otsuji, et al., Clinical Chemistry, Vol. 28, No. 10, 1982, pp. 2121-2124.

[41]   D. S. Young, “Effects of Drugs on Clinical Laboratory Test,” 4th Edition, AACC Press, Washington D.C., 1995.

[42]   Y. Tan, X. Sun, L. Tang, N. Zhang, Q. Han, M. Xu, X. Tan, et al., “Automated Enzymatic Assay for Homocysteine,” Clinical Chemistry, Vol. 49, No. 6, 2003, pp. 10291030.

[43]   E. A. Enas, V. Mohan, M. Deepa, S. Farooq, S. Pazhoor and H. Chennikkara, “The Metabolic Syndrome and Dyslipidemia among Asian Indians: A Population with High Rates of Diabetes and Premature Coronary Artery Disease,” Journal of the Cardiometabolic Syndrome, Vol. 2, No. 4, 2007, pp. 267-275.

[44]   A. Misra, N. K. Vikram, R. Gupta, R. M. Pandey, J. S. Wasir and V. P. Gupta, “Waist Circumference Cutoff Points and Action Levels for Asian Indians for Identification of Abdominal Obesity,” International Journal of Obesity, Vol. 30, No. 1, 2006, pp. 106-111.

[45]   P. S. Jellinger, D. A. Smith, A. E. Mehta, O. Ganda, Y. Handelsman, H. W. Rodbard, M. D. Shepherd and J. A. Seibel, “The AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis,” Endocrine Practice, Vol. 18, No. 1, 2012, pp. 8-11.

[46]   E. Dhanaraj, A. Bhansali, S. Jaggi, P. Dutta, S. Jain, P. Tiwari and P. Ramarao, “Predictors of Metabolic Syndrome in Asian North Indians with Newly Detected Type 2 Diabetes,” The Indian Journal of Medical Research, Vol. 129, No. 5, 2009, pp. 506-514.

[47]   I. A. Syed and W. A. Khan, “Glycated Haemoglobin—A Marker and Predictor of Cardiovascular Disease,” Journal of Pakistan Medical Association, Vol. 61, No. 7, 2011, pp. 690-695.

[48]   R. Mack, B. Skurnick, Y. Sterling-Jean, M. Pedra-Nobre and D. Bigg, “Fasting Insulin Levels as a Measure of Insulin Resistance in American Blacks,” The Journal of Applied Research, Vol. 4, No. 1, 2004, pp. 90-94.

[49]   E. Ekicibasi, A. A. Kaderli, A. R. Kazazoglu and B. Ozdemir, “Association of Microalbuminuria and Fasting Insulin Levels with Presence and Severity of Coronary Artery Disease in Non-Diabetic Cases,” Anadolu Kardiyoloji Dergisi, Vol. 8, No. 1, 2008, pp. 16-21.

[50]   J. Dilley, A. Ganesan, R. Deepa, M. Deepa, G. Sharada, O. D. Williams, et al., “Association of A1C with Cardiovascular Disease and Metabolic Syndrome in Asian Indians with Normal Glucose Tolerance,” Diabetes Care, Vol. 30, No. 6, 2007, pp. 1527-1532.

[51]   F. M. Loehrer, R. Schwab, C. P. Angst, W. E. Haefeli and B. Fowler, “Influence of Oral S-Adenosylmethionine on Plasma 5-Methyltetrahydrofolate, S-Adenosylhomocysteine, Homocysteine and Methionine in Healthy Humans,” The Journal of Pharmacology Experimental Therapeutics, Vol. 282, No. 2, 1997, pp. 845-850.

[52]   A. G. Bostom, H. Silbershatz, I. H. Rosenberg, J. Selhub, R. B. D’Agostino, P. A. Wolf, P. F. Jacques and P. W. Wilson, “Non-Fasting Plasma Total Homocysteine Levels and All-Cause and Cardiovascular Disease Mortality in Elderly Framingham Men and Women,” Formerly Archives of Internal Medicine, Vol. 159, No. 10, 1999, 1077-1080.

[53]   J. D. Kark, J. Selhub, B. Adler, J. Gofin, J. H. Abramson, G. Friedman and I. H. Rosenberg, “Nonfasting Plasma Total Homocysteine Level and Mortality in Middle-Aged and Elderly Men and Women in Jerusalem,” Annals of Internal Medicine, Vol. 131, No. 5, 1999, pp. 321-330.

[54]   S. E. Vollset, H. Refsum, A. Tverdal, O. Nygard, J. E. Nordrehaug, G. S. Tell and P. M. Ueland, “Plasma Total Homocysteine and Cardiovascular and Non Cardiovascular Mortality: The Hordaland Homocysteine Study,” The American Journal of Clinical Nutrition, Vol. 74, No. 1, 2001, pp. 130-136.

[55]   K. Robinson, E. L. Mayer, et al., “Hyperhomocysteinemia and Low Pyridoxal Phosphate: Common and Independent Reversible Risk Factors for Coronary Artery Disease,” Circulation, Vol. 92, No. 10, 1995, pp. 28252830.

[56]   R. R. McLean, P. F. Jacques, et al., “Homocysteine as a Predictive Factor for Hip Fracture in Older Persons,” The New England Journal of Medicine, Vol. 350, No. 20, 2004, pp. 2042-2049.

[57]   L. Broxmeyer, “Heart Disease: The Greatest ‘Risk’ Factor of Them All,” Medical Hypotheses, Vol. 62, No. 5, 2004, pp. 773-779.

[58]   B. S. Raheja and M. Talim, “Homocysteine and Heart Disease in Indian Asians,” The Lancet, Vol. 355, No. 9222, 2000, pp. 2249-2250.

[59]   J. Dierkes, S. Westphal and C. Luley, “Serum Homocysteine Increases after Therapy with Fenofibrate or Bezafibrate,” The Lancet, Vol. 354, No. 9174, 1999, pp. 219-220.

[60]   D. Aronson, P. Bartha, O. Zinder, A. Kerner, W. Markiewicz, O. Avizohar, G. J. Brook and Y. Levy, “Obesity Is the Major Determinant of Elevated C-Reactive Protein in Subjects with the Metabolic Syndrome,” International Journal of Obesity, Vol. 28, No. 5, 2004, pp. 674-679.

[61]   T. Pearson, G. A. Mensah, R. W. Alexander, J. L. Anderson, R. O. Cannon, M. Criqui, Y. Y. Fadl, S. P. Fortmann, et al., “Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals from the Centers for Disease Control and Prevention and the American Heart Association,” Circulation, Vol. 107, No. 3, 2003, pp. 499-511.

[62]   K. G. Alberti, P. Zimmet and J. Shaw, “IDF Epidemiology Task Force Consensus Group. The Metabolic Syndrome a New Worldwide Definition,” The Lancet, Vol. 366, No. 9481, 2005, pp. 1059-1062.

[63]   N. K. Vikram, A. Misra, R. M. Pandey, M. Dwivedi, K. Luthra, V. Dhingra and K. K. Talwar, “Association between Subclinical Inflammation & Fasting Insulin in Urban Young Adult North Indian Males,” Indian Journal of Medical Research, Vol. 124, No. 6, 2006, pp. 677-682.

[64]   J. S. Wasir, A. Misra, N. K. Vikram, R. M. Pandey and K. Luthra, “C-Reactive Protein, Obesity, and Insulin Resistance in Post-Menopausal Women in Urban Slums of North India,” Diabetes and Metabolic Syndrome: Clinical Research and Reviews, Vol. 1, No. 2, 2007, pp. 83-89.

[65]   P. Aparna, A. Betigeri and P. Pasupathy, “Homocysteine and Oxidative Stress Markers and Inflammation in Patients with Coronary Artery Disease,” International Journal of Biological and medical Research, Vol. 1, No. 4, 2010, pp. 125-129.